Eosinophilic granulomatosis with polyangiitis: an overview

Area of Science:

• Immunology
• Rheumatology
• Pathology

Background:

• Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare small vessel vasculitis associated with asthma and eosinophilia.
• Its pathogenesis is multifactorial, involving genetic predispositions and environmental triggers.
• Eosinophils are central to EGPA, acting as effector and immunoregulatory cells.

Purpose of the Study:

• To elucidate the complex pathogenesis of EGPA.
• To understand the role of genetic and acquired factors in EGPA development.
• To explore the immunobiology, clinical phases, and treatment strategies for EGPA.

Main Methods:

• Review of existing literature on EGPA pathogenesis, genetics, and immunology.
• Analysis of cellular and humoral immune responses, including Th-2 bias and B-cell involvement.
• Examination of the characteristic three-phase disease progression (allergic, eosinophilic, vasculitic).

Main Results:

• Genetic factors like HLA-DRB1*04/*07 and IL10.2 haplotype are implicated.
• Environmental factors include allergens, infections, vaccinations, drugs, and silica.
• EGPA exhibits a Th-2 driven immune response with significant eosinophil infiltration and potential B-cell and T-cell interactions.

Conclusions:

• EGPA pathogenesis is complex, involving genetic susceptibility and environmental factors, with eosinophils central to the inflammatory process.
• Understanding the distinct clinical phases and immunological underpinnings guides therapeutic approaches.
• Current treatments include corticosteroids and immunosuppressants, with B-cell depletion (rituximab) showing promise.